Wegovy
-
healthIndia's Generic Drugmakers Disrupt Weight Loss Market with Cheaper Semaglutide
Indian pharma companies launch generic semaglutide, slashing costs up to 70% and aiming to supply the global market.
-
healthWeight-Loss Drugs Show Potential in Reducing Alzheimer's Protein Buildup
A major review suggests popular GLP-1 weight-loss drugs may help limit the molecular hallmarks of Alzheimer's disease, reducing amyloid-beta and tau proteins in preclinical studies.
-
healthMedicare Delays GLP-1 Weight-Loss Drug Program Amid Insurer Concerns
Medicare will offer GLP-1 weight-loss drugs via a temporary bridge program, delaying a new initiative due to insurer hesitations. Permanent integration remains uncertain.
-
healthGenetic Variants May Explain Why GLP-1 Drugs Fail for Some Patients
New research suggests specific genetic variations in the PAM gene could be the reason why GLP-1 medications like Ozempic are ineffective for approximately 10% of individuals with type 2 diabetes.
-
healthNew Study Reveals Unreported Side Effects of Popular Weight-Loss Drugs
A University of Pennsylvania study analyzing Reddit posts uncovers potential new side effects of GLP-1 agonists like Ozempic and Mounjaro, beyond common gastrointestinal issues.
-
techNovo Nordisk Taps OpenAI for AI-Driven Drug Development
Novo Nordisk partners with OpenAI to accelerate drug discovery, enhance manufacturing, and improve efficiency using artificial intelligence in the competitive obesity drug market.
-
healthNHS to Offer Semaglutide to 1.2 Million Cardiovascular Patients
NICE approves Wegovy for high-risk patients following major clinical trials showing 20% reduction in cardiovascular events.
-
healthStopping GLP-1 Drugs Erases Heart Benefits Fast, Study Warns
New research shows cardiovascular protection from Ozempic and similar drugs vanishes within months of stopping - with lasting damage.